RVTY vs SLP
RVTY: Revvity provides a comprehensive suite of life science and diagnostic technologies, powering workflows from research discovery to clinical breakthroughs. SLP: Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences industry.
Side-by-side fundamentals
| Metric | RVTY | SLP | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $114.24 | $18.34 | |
| Market cap as of 2026-08-08 | $12.7B | $371M | |
| P/E as of 2026-08-08 | 53.75 | 45.71 | SLP lower |
| PEG as of 2026-08-08 | 5.81 | n/a | |
| Net margin as of 2026-08-08 | +8.2% | +9.9% | SLP higher |
| Gross margin as of 2026-08-08 | +55.0% | +63.4% | SLP higher |
| Operating margin as of 2026-08-08 | +12.3% | +14.0% | SLP higher |
| ROE as of 2026-08-08 | +3.3% | +6.2% | SLP higher |
| ROA as of 2026-08-08 | +2.0% | +5.7% | SLP higher |
| Debt / equity as of 2026-08-08 | 0.44 | 0.00 | SLP lower |
| Revenue growth (YoY) as of 2026-08-08 | +4.0% | +2.1% | RVTY higher |
| Revenue CAGR (3y) SEC XBRL | -9.3% | +13.7% | SLP higher |
| Dividend yield as of 2026-08-08 | +0.2% | +0.6% | SLP higher |
| Dividend streak (yrs) SEC XBRL | 3 | 5 | SLP higher |
| Beta as of 2026-08-08 | 1.07 | 1.32 | |
| 1-year return as of 2026-08-06 close | +33.0% | +40.6% | SLP higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.